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Abstract
Objective
To assess whether organisations that develop health care guidelines have conflict of inter-
est (COI) policies and to review the content of the available COI policies.
Methods
Survey and content analysis of COI policies available in English, French, Spanish, and Ital-
ian conducted between September 2014 and June 2015. A 24-item data abstraction instru-
ment was created on the basis of guideline development standards.
Results
The survey identified 29 organisations from 19 countries that met the inclusion criteria. From
these organisations, 19 policies were eligible for inclusion in the content analysis. Over one-
third of the policies (7/19, 37%) did not report or did not clearly report whether disclosure
was a prerequisite for membership of the guideline panel. Strategies for the prevention of
COI such as divestment were mentioned by only two organisations. Only 21% of policies (4/
19) used criteria to determine whether an interest constitutes a COI and to assess the sever-
ity of the risk imposed.
Conclusions
The finding that some organisations, in contradiction of widely available standards, still do
not have COI policies publicly available is concerning. Also troubling were the findings that
some policies did not clearly report critical steps in obtaining, managing and communicating
disclosure of relationships of interest. This in addition to the variability encountered in con-
tent and accessibility of COI policies may cause confusion and distrust among guideline
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users. It is in the interest of guideline users and developers to design an agreed-upon, com-
prehensive, clear, and accessible COI policy.
Introduction
The problem of conflict of interest (COI) in health care guidelines has received growing atten-
tion from health care guideline developers and users in recent years. Inadequate management
of COI can result in bias and have important implications for public confidence in both the
guidelines and the organisations that produce them [1–5]. In response to this problem, numer-
ous recommendations for improving the identification and management of COI in guideline
development have been issued [6–12]. The U.S. Institute of Medicine (IOM) and Guidelines
International Network (G-I-N), a global network of individuals and organisations interested
in guidelines [www.g-i-n.net/about-g-i-n], have both produced standards for creating trust-
worthy guidelines [13–16] which include guiding principles to identify and manage COI. The
importance of recording and addressing COI is also reflected in the appraisal criteria of
AGREE II [17], an international tool for assessing the quality and reporting of health care
guidelines.
Research on COI in guidelines has focused mainly on compliance with IOM and AGREE II
standards [18–21] as well as on the prevalence of COI among members of guideline develop-
ment groups [20,22–29]. Findings suggest that adherence to these standards is poor [18–21]
and COI are both common [19,20,23,25–29] and rarely disclosed [23,26,27,29].
For guideline developers, a first step in addressing COI is to have relevant policies and pro-
cedures in place. To our knowledge only one previous study [30] has surveyed and examined
the content of the COI policies of guideline developers. This cross-sectional study of 37 organi-
sations producing a ‘large’ number of guidelines (defined as five or more guidelines listed in
the National Guidelines Clearinghouse in 2009–2010) compared COI policies to IOM stan-
dards. Only 17 (17/37, 46%) of the guideline developers studied had a COI policy for guide-
lines in place and not one policy adhered to all 7 relevant IOM standards [14]. The study was
limited to English-language guideline developers and nearly two-thirds of these organisations
(24/37, 65%) were in the United States, with the remainder representing four other countries:
Canada (5), the United Kingdom (5), New Zealand (2), and the Netherlands (1).
This study expands upon previous research to examine the COI policies of an international
sample that includes non-English-language guideline developers.
Objectives
The aim of our study was to assess whether and how organisations address COI issues related
to guideline development, and to identify and quantify problematic areas of underreporting.
We set out to capture a cross-sectional sample of worldwide guideline development organi-
sations and to examine the content of their policies on COI available in English, French, Span-
ish and Italian through a predefined data abstraction instrument.
Methods
Selection of guideline development organisations
Between September 2014 and June 2015 we conducted an Internet search and content analy-
sis of the COI policies of organisations who have a programme of health care guideline
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development covering a wide range of health topics i.e. a programme not limited to a particu-
lar disease or condition or to group or subgroup of diseases or conditions.
We obtained a preliminary list of 53 organisations by searching in the G-I-N database
(http://www.g-i-n.net/membership/members-around-the-world) filtered by “activities” and
“guideline development” (accessed September 25, 2014).
This list was integrated with a list of organisations obtained through an evidence inventory
[31] of surveys of guideline developer organisations. We performed the evidence inventory to
list what surveys were available on guideline developer organisations. Studies were sought
from MEDLINE (1 January 2009 to 1 August 2014) and limited to English language (S1
Table). The search identified 217 articles. One author (CM) screened the titles and abstracts of
all retrieved articles. A survey of European guideline developers was found and included [32]
with one companion report [33]. We also included an article [34] which listed guideline hand-
books/manuals to identify further guideline developers.
From these studies 60 additional organisations were identified, of which 21 were duplicates,
leaving a sample of 92 organisations (S2 Table). In order to identify a manageable subsample
of organisations that had the potential to produce guidelines with the most wide-ranging
impacts on health, we pragmatically restricted our sample further to exclude organisations
whose guideline programmes are limited to single disease areas or single health professions.
Identification of COI policies
We searched the websites of included organisations for documents that described the guideline
development process (manuals, handbooks, methodology articles, webpages), disclosure of
relationships of interest (DOI) forms, and any other available documents that mentioned COI
issues related to guideline development and available in English, French, Italian or Spanish,
with no date restrictions. We did not contact organisations directly to obtain additional infor-
mation, but used only information publicly available.
We aimed to include documents that addressed COI in guideline development and that
provided data for at least two of the items included in each of the following overarching items
of the data abstraction instrument: “Information required for disclosure of financial and nonfi-
nancial relationships” and “Procedures for collecting, reviewing disclosure of relationships of
interest and managing conflict of interest” (Table 1). We called a document meeting these cri-
teria a “COI policy”. In the content analysis we distinguished the term “relationship (financial
and nonfinancial) of interest” and “conflict of interest”. The term “relationship of interest”
refers to any interest or activity requested to be declared that may be judged to constitute a
COI. Consequently we used the term “disclosure of relationships of interest” to indicate the
step that precedes the review of DOI.
Data extraction and analysis
We developed a 24-item data abstraction instrument (Table 1) based on recommendations
and standards of COI proposed by the IOM [13,14] and G-I-N [15]. The types of financial rela-
tionships and nonfinancial relationships considered in this study were based on those listed by
IOM [13,14] and G-I-N [15].
One author (CM) abstracted information on each organisation and each COI policy into
the predefined template and those data were checked by a second author (CF, ST). When there
was disagreement regarding the content of a particular COI policy this was resolved by discus-
sion. If the policy was updated during the period of data collection, we updated the abstracted
information. Where disclosure forms were publicly available, data from these were integrated
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with the data extracted from the policies. Where inconsistencies were found, the information
in the policy prevailed.
Results
Twenty-six organisations were excluded from the 92 identified as their remit was restricted to
single disease specialties or single professional groups (S2 Table). Of the 66 remaining organi-
sations, 11 were subsequently excluded because they did not provide documents on guideline
development in English, French, Italian, or Spanish; 15 because they did not provide publicly
accessible documents on guideline development or COI issue guideline related; 5 because their
website was not found or not accessible and 6 because they were not guideline developers.
The documents of the remaining 29 organisations (Table 2) were assessed for the presence
of a COI policy according to our definition. Of these organisations 21 were governmental, 4
were not for profit and 4 were professional associations. Ten organisations (10/29, 34%) were
excluded from content analysis for the following reasons: 8 because their documents did not
mention or provided insufficient information on COI, 1 because its handbook referred to an
included parent organisation’s COI policy and 1 because its handbook was superseded by the
handbook of its collaborating organisation. In the end 19 COI policies were included in the
Table 1. Data abstraction instrument.
General
Name of organisation
Country
Type of organisation
Document on guideline development
Conflict of interest policy presence
Date of conflict of interest policy
Source of conflict of interest policy (handbooks/methodological articles/webpages)
Definition(s) of conflict of interest
Information required for disclosure of financial and nonfinancial relationships
Types of financial relationships
Financial threshold considered
Types of nonfinancial relationships
Relevance to the guideline topic/issue of the guideline considered
Time period for disclosure considered
About whom is disclosure of relationships of interest collected
Information on financial and nonfinancial relationships of the individual’s personal relationships considered
Procedures for collecting, reviewing disclosure of relationships of interest and managing conflict
of interest
Disclosure of relationships of interest required prior to selection of the guideline development group
Who reviews disclosure of relationships of interest and make decision
Assessment of risk performed
Divestment required prior to selection of the guideline development group
Exclusion procedure applied
Relationship prohibited
Reported penalties for non-disclosure
Processes for recording and making publicly accessible disclosure of relationships of interest
Description of the process to record disclosure of relationships of interest
Completed disclosure forms publicly accessible
doi:10.1371/journal.pone.0166485.t001
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Table 2. Characteristics of the included organizations (N = 29).
Organisation Country Type of
organisation
Document on
guideline
development
COI policy Date of
COI policy
Source of COI policy
American College of Physicians
(ACP)
USA Professional Yes [35] Yes 2010 Science journal [35]
Belgian Health Care Knowledge
Centre/Federal Centre of Health
Care Expertise (KCE)
Belgium Government Yes [36] No Not
applicable
Not applicable
Canadian Task Force on Preventive
Health Care (CTFPHC)
Canada Government Yes [37] Yes 2014 Handbook [37]
US Centers for Disease Control and
Prevention Healthcare- Infection
Control Practices Advisory
Committee (CDC-HICPAC)
USA Government Yes [38] No Not
applicable
Not applicable
US Centers for Disease Control and
Prevention Advisory Committee on
Immunization Practices (CDC-ACIP)
USA Government Yes [39,40] Yes 2009 Science journal [40]
Centro National de Excelentia
Tecno´logica en Salud (CENETEC)
Mexico Government Yes [41] Yes 2007 Handbook [41]
Conseil Scientifique du Domaine de
la Sante´ (CSDS)
Luxembourg Government Yes [42] No Not
applicable
Not applicable
Current Care Guidelines /The
Finnish Medical Society Duodecim
(FMSD)
Finland Professional Yes [43] Yes 2014 Webpage (flow chart)
[43]
Instituto de Evaluacio´n Tecnolo´gica
en Salud (IETS)
Colombia Not for profit Yes [44] Yes 2014 Handbook [44]
German Association of the Scientific
Medical Societies (AWMF)
(Arbeitsgemeinschaft der
Wissenschaftlichen Medizinischen
Fachgesellschaften)
Germany Professional Yes [45] Yes 2012 Handbook [45]
German Agency for Quality in
Medicine (AQuMed A¨ ZQ) (Das
A¨ rztliche Zentrum fu¨r Qualita¨t in der
Medizin)
Germany Professional Yes [46] Yes (referred to
AWMF) [45]
Not
applicable
Not applicable
Guı´aSalud (GS) Spain Government Yes [47] Yes 2007 Handbook [47]
Haute Autorite´ de Sante´ (HAS) France Government Yes [48,49] Yes 2013 Stand alone document
posted in the website;
other related
information in the
guideline handbook
[48,49]
Kaiser Permanente (KP) USA Not for profit Yes [50] No Not
applicable
Not applicable
Ministerio de Salud (MS) Peru Government Yes [51] No Not
applicable
Not applicable
Ministerio de Salud y Proteccio´n
Social (MSPS)
Colombia Government Yes [52] Yes (superseded by
handbook of IETS
as collaborating
organisation [44])
Not
applicable
Not applicable
National Board of Health and
Welfare (SS) (Socialstyrelsen)
Sweden Government Yes [53] No Not
applicable
Not applicable
King Saud bin Abdulaziz University
for Health Sciences, National and
Gulf Center for Evidence Based
Health Practice (EBHP)
Saudi Arabia Government Yes [54] No Not
applicable
Not applicable
(Continued )
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content analysis from 13 countries and 1 intergovernmental organisation. Fig 1 provides a
description of the inclusion of organisations at each stage.
Conflict of interest policies
The 19 COI policies were accessible in various formats. Many organisations included their pol-
icy in a guideline handbook [37,41,44,45,47,63,65–68] (10/19, 53%). Six organisations
[48,56,57,59,61,64] (6/19, 32%) posted their COI policies on their website as a stand alone doc-
ument. Three of these provided additional information about management of COI in their
guideline handbook [49,58,62] with reference to the COI policy posted in the website. The
remainder of the organisations included information on COI policy on a webpage as a flow
chart [43] or in a methodological article posted on the organisation’s website [35,40] (Table 2).
The date of the COI policy was determined by considering the date of the document itself if
published as stand alone document or of the corresponding date of the handbook/manual,
methodological article, or webpage where the COI policy was included. The date of the 18
Table 2. (Continued)
Organisation Country Type of
organisation
Document on
guideline
development
COI policy Date of
COI policy
Source of COI policy
The National Clinical Effectiveness
Committee (NCEC)
Ireland Government Yes [55,56] Yes 2013 Stand alone document
posted in the website
[56]
National Health and Medical
Research Council (NHRMC)
Australia Government Yes [57] Yes 2012 Stand alone document
posted in the website
[57]
National Institute for Health and Care
Excellence (NICE)
UK-England Government Yes [58,59] Yes 2014 Stand alone document
posted in the website;
other related
information in the
guideline handbook
[58,59]
National Institute of Quality and
Innovation (NIKI) (Na´rodny´ Insˇtitu´t
Kvality a Inova´ciı´)
Slowakia Not for profit Yes [60] No Not
applicable
Not applicable
Scottish Intercollegiate Guidelines
Network (SIGN)
UK-Scotland Government Yes [61,62] Yes 2014 Stand alone document
posted in the website;
other related
information in the
guideline handbook
[61,62]
Sistema Nazionale Linee Guida
(SNLG)
Italy Government Yes [63] Yes 2004 Handbook [63]
Therapeutic Guidelines Limited
(TGL)
Australia Not for profit Yes [64] Yes 2014 Stand alone document
posted in the website
[64]
Universidad Nacional de Colombia,
Instituto de Investigaciones Clinicas,
Facultad de Medicina (GETS)
Colombia Government Yes [65] Yes Not
reported
Handbook [65]
University of Tartu Medical Faculty,
Estonian Health Insurance
Foundation, World Health
Organization (HE-TU)
Estonia Government Yes [66] Yes 2011 Handbook [66]
US Preventive Services Task Force
(USPSTF)
USA Government Yes [67] Yes 2008 Handbook [67]
World Health Organization (WHO) Intergovernmental Government Yes [68] Yes 2014 Handbook [68]
doi:10.1371/journal.pone.0166485.t002
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policies for which a date could be determined ranged from 2007 to 2014. Of the 18 policies 7
were published in 2014 (7/18, 39%), 5 were dated between 2011–2013 (5/18, 28%) and 6 were
dated prior 2011 (6/18, 33%). Around one third of the policies (Table 3) [37,40,41,43,63,67]
(6/19, 32%) did not report a definition of the term “conflict of interest” and the remaining pol-
icies provided heterogeneous definitions.
Disclosure of relationships of interest
All included policies outlined categories of financial relationships but characterization of spe-
cific types of nonfinancial relationships was lacking in some cases [39,40,43,47,63] (4/19, 21%)
(Table 4). Policies varied in the categories of information that need to be disclosed and in
whether or not disclosures were limited to information relevant to the content/topic of the
guideline.
Fig 1. Organisation identification and inclusion criteria.
doi:10.1371/journal.pone.0166485.g001
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Table 3. Definition of conflict of interest by organisation.
Organisation Definition of conflict of interest
ACP [35] “Potential financial or nonfinancial conflicts of interest that refer to relationships that a
reasonable reader of a guideline would wish to know about and that if not disclosed
could compromise the interpretation of the ACP guideline”
CTFPHC [37] Not reported
CDC-ACIP
[39,40]
Not reported
CENETEC [41] Not reported
FMSD [43] Not reported
IETS [44] The activities that may create potential conflicts of interest occur in those circumstances
where professional judgment on a primary interest, such as patient’s welfare or the
validity of research, may be influenced by a secondary interest, such as financial gain,
prestige, personal or professional advancement
AWMF [45] Not reported
GS [47] The activities that may create potential conflicts of interest occur in those circumstances
where professional judgment on a primary interest, such as patient’s welfare or the
validity of research, may be influenced by a secondary interest, such as financial gain,
prestige, personal or professional advancement [69]
HAS [48,49] The relationships of interests may give rise to the conflict of interest. These are
therefore two distinct concepts. A conflict of interest arises from a situation in which the
relationships of interest of a person may affect, by their nature or intensity, his
impartiality or independence in the exercise of his mission regarding the matter under
discussion
NCEC [55,56] “In the context of the work of the NCEC, a COI is any interest that could result in bias in
the work or decision making processes of the NCEC”
NHMRC [57] “Financial interests: an interest must be declared as a potential conflict when benefits or
losses either in money or in kind have occurred or may occur at a level that might
reasonably be perceived to affect a person’s judgment in relation to a fair decision about
evidence and their participation in group decision making”. “Other relationship: an
interest must be declared as a potential conflict when a strong position or prejudice or
familial connection or other relationship held by a person could reasonably, or be
perceived to, affect a person’s judgment in relation to fair decision about evidence and
their participation in group decision-making including making an effort to arrive at a
consensus”
NICE [58,59] “A conflict of interest arises when the judgment of someone involved in the work of NICE
may be compromised, by the financial or other considerations set out in this policy”
SIGN [61,62] “Competing interests are defined as any interest of the person, their partners or close
relatives (personal) or their department/employer/business (non-personal) which may
potentially influence the content, including recommendations, of SIGN guidelines”
SNLG [63] Not reported
TGL [64] “Interest statements must comprise a declaration of any interests that may be capable
of influencing advice or decisions relating to the operation or activities of TGL, or that
may affect the integrity and reputation of TGL”
GETS [65] The conflict of interest arises when an individual or organisation considers alternatives
where interests or benefits coexist and there is a duality of commitment [70]. The
conflict is evident when the option that provides personal benefits is selected at the
detriment of the option more adherent to ethical principles and general interest
HE-TU [66] “Any interest which may affect or may reasonably be perceived to affect, the expert
objectivity and independence”
USPSTF [67] Not reported
WHO [68] “A conflict of interest is a set of circumstances that creates a risk that professional
judgment or actions regarding a primary interest will be unduly influenced by a
secondary interest” [14]. “Any interest declared by an expert that may affect or
reasonably be perceived to affect the expert’s objectivity and independence in providing
advice to WHO”
doi:10.1371/journal.pone.0166485.t003
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Table 4. Disclosure of relationships of interest.
Organisation What are the
types of financial
relationships
considered? (a)
Is financial
threshold
considered?
What are the types
of nonfinancial
relationships
considered? (b)
Is relevance
to the
guideline
topic
considered?
Is time period for
disclosure
considered?
About whom is DOI
collected?
Is information for
disclosure on
financial and/or
nonfinancial
relationships of
the individual’s
personal
relationships
considered?
ACP [35] Paid employment.
Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Research grant or
salary support.
Patent or royalties.
Equity/stock or
shares. Gift.
Others
No Development of
related guidelines
and standards,
educational material.
Having personal
convictions (political,
religious, ideological
or other) related to
the guideline topic
that may interfere
with an unbiased
evidence review or
recommendation
process. Member of
advisory board,
committee,
organisations,
advocacy group.
Others
Yes Yes. Present and
within the past
three years
Members ACP,
board of regents,
clinical guideline
committee and ACP
staff
Yes. “Spouse” and
limited to
nonfinancial
relationships
“friend, spouse,
family member,
current or previous
mentor or
adversary”
CTFPHC [37] Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Research grant or
salary support.
Equity/stock or
shares. Gift.
Others
No Publications, trials,
systematic reviews.
Member of advisory
board, committee,
organisations,
advocacy group.
Others
Yes No Potential participant
in a CTFPHC led
initiatives (peer
reviewer, clinical
expert, review team
member, CTFPHC
members)
Yes. “Spouse and
immediate family
members”
CDC-ACIP
[39,40]
Paid employment.
Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Patent or royalties.
Others
No Not reported No No Members of
CDC-ACIP
Yes. “Immediate
family member”
CENETEC
[41]
Paid employment.
Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Patent or royalties
No Others Yes No Members of the
guideline
development group
No
(Continued )
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Table 4. (Continued)
Organisation What are the
types of financial
relationships
considered? (a)
Is financial
threshold
considered?
What are the types
of nonfinancial
relationships
considered? (b)
Is relevance
to the
guideline
topic
considered?
Is time period for
disclosure
considered?
About whom is DOI
collected?
Is information for
disclosure on
financial and/or
nonfinancial
relationships of
the individual’s
personal
relationships
considered?
FMSD [43] Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Research grant or
salary support.
Patent or royalties.
Others
No Not reported No Yes. 36 months
prior submission
of work only for
some types of
relationships
Members of the
guideline
development group
No
IETS [44] Paid employment.
Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Research grant or
salary support.
Equity/stock or
shares. Others
No Development of
related guidelines
and standards,
educational material.
Publications, trials,
systematic reviews.
Others
No Yes. 24 months
before only for
some types of
relationships
Potential
participants in the
guideline work, any
individual who has
direct input to the
guideline (members
of the guideline
development group:
clinicians, patients,
methodologists,
external advisors,
peer reviewers)
Yes. First-degree
relative, spouse,
partner (pareja de
hecho), children
for whom the
member is legally
responsible
AWMF [45] Paid employment.
Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Research grant or
salary support.
Patent or royalties.
Equity/stock or
shares.
No Having personal
convictions (political,
religious, ideological
or other) related to
the guideline topic
that may interfere
with an unbiased
evidence review or
recommendation
process. Member of
advisory board,
committee,
organisations,
advocacy group
No Yes. Within the
last 3 years
Steering committee
members,
coordinators and
work group leaders,
and all participants
in the guideline work
Yes. “Personal/
professional
partners”
GS [47] Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Research grant or
salary support.
Equity/stock or
shares. Others
No Not reported No Yes. Present and
3 years before
Participants in the
guideline work and
anyone who has
direct input into the
guideline (including
experts, patient/
caregiver)
No
(Continued )
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Table 4. (Continued)
Organisation What are the
types of financial
relationships
considered? (a)
Is financial
threshold
considered?
What are the types
of nonfinancial
relationships
considered? (b)
Is relevance
to the
guideline
topic
considered?
Is time period for
disclosure
considered?
About whom is DOI
collected?
Is information for
disclosure on
financial and/or
nonfinancial
relationships of
the individual’s
personal
relationships
considered?
HAS [48,49] Paid employment.
Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Research grant or
salary support.
Patent or royalties.
Equity/stock or
shares. Others
No Publications, trials,
systematic reviews.
Member of advisory
board, committee,
organisations,
advocacy group.
Others
No Yes. Present and
5 years before
Members of the
guideline
development group,
individual experts,
personnel of HAS
Yes. Spouse,
cohabitant, pacsè
(who has signed
the pacte civil de
solidarite´), parents
and the children of
this; individual’s
children, parents
NCEC [55,56] Paid employment.
Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Patent or royalties.
Equity/stock or
shares. Gift
No Development of
related guidelines
and standards,
educational material
No No Committee
members of NCEC,
members of the
guideline
development group
No
NHMRC [57] Paid employment.
Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Research grant or
salary support.
Equity/stock or
shares. Gift.
Others
No Development of
related guidelines
and standards,
educational material.
Publications, trials,
systematic reviews.
Member of advisory
board, committee,
organisations,
advocacy group.
Others
Yes Yes. Over the
past 3 years
Chair and other
members of the
guideline
development group
Yes. “Immediate
family members
(partner and
dependent
children)”
NICE [58,59] Paid employment.
Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Research grant or
salary support.
Equity/stock or
shares. Patent or
royalties. Others
No Development of
related guidelines
and standards,
educational material.
Publications, trials,
systematic reviews.
Member of advisory
board, committee,
organisations,
advocacy group.
Others
No Yes. 12 months
before joining an
advisory
committee or
during the period
of membership of
an advisory
committee
All Committee
members and
anyone who has
direct input into the
guideline including
the developer, the
evidence review
team, the expert
witnesses
Yes. “Spouse or
partner living in the
same residence as
the individual, as
well as children
and adults (who
may or may not be
living in the same
residence) for
whom the
individual is legally
responsible”
(Continued )
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Table 4. (Continued)
Organisation What are the
types of financial
relationships
considered? (a)
Is financial
threshold
considered?
What are the types
of nonfinancial
relationships
considered? (b)
Is relevance
to the
guideline
topic
considered?
Is time period for
disclosure
considered?
About whom is DOI
collected?
Is information for
disclosure on
financial and/or
nonfinancial
relationships of
the individual’s
personal
relationships
considered?
SIGN [61,62] Paid employment.
Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Research grant or
salary support.
Equity/stock or
shares. Gift.
Others
No Member of advisory
board, committee,
organisations,
advocacy group
No Yes. The year
prior to the
declaration, and
the year following
the declaration
Members of SIGN
and anyone who
has direct input to
the guideline
(members of the
guideline
development group,
peer reviewers,
advisors)
Yes. “Partners or
close relatives”
SNLG [63] Paid employment.
Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Equity/stock or
shares. Patent or
royalties
No Not reported Yes No Members of
guideline
development group
No
TGL [64] Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Research grant or
salary support.
Equity/stock or
shares. Patent or
royalties. Others
No Member of advisory
board, committee,
organisations,
advocacy group.
Others
Yes- Yes. Five past
years, current
and planned
activities
Director and staff of
TLG, members of
expert group,
external reviewers
Yes. “Associate: a
member of the
person’ family, or
a business or
professional
colleague or
partner”
GETS [65] Paid employment.
Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Research grant or
salary support.
Equity/stock or
shares. Gift.
Others
No Development of
related guidelines
and standards,
educational material
No Yes. Last 3 years Any individual who
has direct input to
the guidelines
including external
collaborators and
patients
Yes. Familiar
(Continued )
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Table 4. (Continued)
Organisation What are the
types of financial
relationships
considered? (a)
Is financial
threshold
considered?
What are the types
of nonfinancial
relationships
considered? (b)
Is relevance
to the
guideline
topic
considered?
Is time period for
disclosure
considered?
About whom is DOI
collected?
Is information for
disclosure on
financial and/or
nonfinancial
relationships of
the individual’s
personal
relationships
considered?
HE-TU [66] Paid employment.
Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Research grant or
salary support.
Equity/stock or
shares. Patent or
royalties
Yes Member of advisory
board, committee,
organisations,
advocacy group.
Others
Yes Yes. Within the
past 3 years
Panel members.
The chair of the
panel
Yes. “Spouse,
adult children or
siblings, close
professional
colleagues,
administrative unit
or department “
USPSTF [67] Paid employment.
Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Equity/stock or
shares. Patent or
royalties
Yes Member of advisory
board, committee,
organisations,
advocacy group.
Others
Yes Yes. Two months
prior to the
meeting and
continues until
the final reports
are completed.
Past five years, in
case of expert
testimony or
expert review in a
medical
malpractice case
on a given Task
Force-related
topic
Task Force
members
Yes. “Spouse and
dependent
children”
WHO [68] Paid employment.
Paid consultancy
or speaking
engagement,
honoraria,
advisory role,
board
membership.
Research grant or
salary support.
Equity/stock or
shares. Patent or
royalties. Others
Yes Publications, trials,
systematic reviews.
Member of advisory
board, committee,
organisations,
advocacy group.
Others
Yes No Members of the
guideline
development group,
systematic review
team,
methodologists,
external review
group if they
represent
themselves
Yes. “Individual’s
immediate family
members (defined
as the spouse, or
partner with whom
one has a close
personal
relationship, and
the children)”
(a) Types of financial relationships considered to perform the content analysis Paid employment. Paid consultancy or speaking engagement,
honoraria, advisory role, board membership. Research grant or salary support. Patent or royalties. Equity/stock or shares. Gift. Others (e.g., travel grant,
attending educational events)
(b) Type of nonfinancial relationships considered to perform the content analysis Development of related guidelines and standards, educational
material. Publications, trials, systematic reviews. Having personal convictions (political, religious, ideological or other) related to the guideline topic that may
interfere with an unbiased evidence review or recommendation process. Member of advisory board, committee, organisations, advocacy group. Others
(e.g., expert testimony, public statement, speech, lecture, opinion leader, other reputational risks)
doi:10.1371/journal.pone.0166485.t004
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Concerning the item “who is required to report on relationships of interest”, all policies
stated that a declaration is collected from members of the guideline development group/panel/
committee but a minority [37,44,58,59,61,62,68] (5/19, 26%) detailed additional disclosures
from staff involved in a standard guideline development process, for example, guideline meth-
odologists, systematic review team, reviewers and advisors. In contrast, policies were much
more likely [35,37,39,40,44,45,48,49,57,58,59,61,62,64–68] (14/19, 74%) to require the disclo-
sure of close personal relationships.
Procedures for collecting, reviewing DOI and managing COI
The majority of policies explicitly reported that DOI is requested before appointment of the
members of the guideline development group [37,39,40,44,47,48,49,57–59,64–68] (12/19,
63%), while the remaining seven policies [35,41,43,45,55,56,61–63] (7/19, 37%) did not report
or were unclear as to whether this important practice was actually used (Table 5).
Regarding the item “who reviews DOI and makes decision” of the 16 organisations report-
ing on this issue [35,37,39,40,44,45,47–49,55–59,61,62,64–68] (16/19, 84%) the chair and/or
the members of the guideline development group were the most cited responsible entity
[35,37,44,45,47,57–59,61,62,64–66] (11/16, 69%). In contrast, only 2 organisations [67,68] (2/
16, 13%) appeared to rely exclusively on a committee as an independent entity to review DOI
and to devise a management plan across the entire guideline development process.
All organisations reported procedures for exclusion of members with conflicts but divest-
ment was considered a requirement only by 2 organisations [39,40,57] (2/19, 11%), and prohibi-
tion of specific relationships by 3 organisations [37,39,40,67]. Only 4 policies [44,48,49,58,59,68]
(4/19, 21%) specified an “assessment of risk”, defined as a procedure and criteria to assess
whether a relationship of interest constitutes a COI and to evaluate the potential harm of the
COI identified [13].
Procedures for recording and public disclosure of DOI
The majority of organisations reported a description of the procedures to record DOI
[37,41,43–45,47–49,55–59,61,62,64,66–68] (15/19, 79%) whereas four did not address this
issue [35,39,40,63,65] (4/19, 21%) (Table 5).
Of those policies that described activities to record DOI, the original completed DOI forms
were reported to be publicly accessible on the website and/or in the published guideline by
seven organisations [37,44,47,48,49,57,64,66] (7/15, 47%) with some exceptions. For example,
one organisation stated DOI will be made public on the organisation website but”exception to
this requirement will be by Chief Executive Officer in appropriate circumstances” [57].
Two organisations published in the guideline and/or website a summary of the DOI infor-
mation [61,62,68] while other two [55,56,67] kept this information confidential although one
of these mentioned the possibility of access upon request under state law [67].
Discussion
We found that of the 29 organisations corresponding to our eligibility criteria we were not
able to identify COI policies for approximately one in four organisations (8/29, 28%). Failure
of guideline developer organisations to adopt a publicly accessible COI policies related to
guideline development has also been reported elsewhere in literature. For example, in the
above mentioned cross-sectional study of Norris et al. [30] only 46% of the 37 surveyed organi-
sations had a COI policy directly related to health care guidelines. These findings along with
the data from our study suggest that the absence of a COI policy might be one of the reason
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behind the phenomenon of underreporting of COI in guidelines [23,26,27,29] as well as the
observed uneven adherence to current standards on COI in guidelines [18–21].
We also found that many organisations provided no or unclear information pertaining to
some items of our data abstraction instrument. In our view, a particularly troubling area in
which COI policies need to be improved is that of guideline panel selection and composition.
More attention to this issue has been advocated to reduce of the potential for COI to create
bias [10,12,28]. Nevertheless, in our investigation about one-third of the policies did not report
or did not clearly report whether disclosure was a prerequisite for panel selection. Addition-
ally, preventive strategy such as divestment [13,15] and prohibition [13] were rarely
mentioned.
A second key area in which COI policies need to be improved is the management of the dis-
closed information, particularly regarding the practices of “the assessment of risk” which is
defined as “practices and criteria used to determine if a relation of interest constitutes a COI
and to assess the potential for harm of the COI identified” [13]. It is encouraging that the poli-
cies surveyed were directed at the most common relationships of interest in support of the
identification of COI. However a policy for systematic and transparent management of the dis-
closed information was uncommon. Few organisations clearly stated what practices and crite-
ria were used to determine whether a relation of interest constitutes a COI and to assess the
potential for harm of the COI identified. The translation of the disclosed information into a
decision or measures taken to limit the likelihood of undue influence of COI is a critical step.
This step should be explicit and transparent to reduce the flexibility of the organisations in
addressing financial and nonfinancial ties as well as to assure the ability of the informed reader
to appraise the validity of decisions on COI issue.
In terms of the management and monitoring of the disclosed information IOM recom-
mends that organisations should create a COI committee (Recommendation 3.1) [13]. In this
regard we found that few organisations have felt the need or identified the necessary resources
to have a dedicated infrastructure to act as a third party providing independent review of DOI
and managing COI across all the phases of guideline development process.
Most organisations relied on the same group of individuals who develop the guidelines to
handle the disclosed cases. This is of particular concern if considered in the context of the evi-
dence of guideline chairs and panel members with a high proportion of conflicts [20,25].
Apart from an improved consistency in decisions taken across guidelines, in our view a “con-
flict of interest committee” could avoid administrative burden for the chair, co-chair and
members of the guideline group and more importantly could consistently implement proce-
dures for the monitoring and enforcement of the policies.
Furthermore our study underlines the issue of variation across policies in keeping with the
findings of Norris et al. [30]. We found that the policies varied in their content, for example in
the definition of COI (when provided), in the categories and details of the information
required to be disclosed, in the time frame for disclosure, in establishing or not establishing a
threshold, and in detailing who is required to declare a relationship of interest. Our sample
included organisations from 13 countries and one intergovernmental organisation, so this var-
iation in part probably reflects cultural, legal and administrative differences across countries as
well as differences in organisational values and interests.
We noted that the policies were also variable in format and accessibility across the organisa-
tions, limiting the ability of the guideline user to obtain a clear and complete picture of the
strategy to address COI throughout the guideline development process. An important finding
is that less than half of the included organisations reported that the information from com-
pleted DOI forms was publicly accessible without restriction. Again, notwithstanding cultural,
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legal and administrative issues, the guideline user has the right to assess the completeness of
the disclosure of COI as well as the consistency with which the policy is implemented.
This study contributes to the literature on the quality of guidelines by demonstrating, using
an innovative sampling method and highly detailed data extraction, that COI remains an area
that requires attention from guideline users and improvement from many guideline develop-
ment organisations. The study confirms previous research that has drawn the same conclu-
sions about COI from different samples of guidelines. The study also has some limitations that
deserve comment.
First, organisations may have practices which are not fully reflected in the written COI poli-
cies or do have policy but not publicly available. However, we decided to rely only on informa-
tion on COI policies publicly accessible on website since we consider accessibility an essential
element of a transparent COI policy. As pointed out by IOM, COI policies should be compre-
hensible and accessible to the individuals and institutions that may be affected [13]. We rec-
ommend that the organisations that disseminate their own health care guidelines should
provide public information on their strategies to identify and manage COI through an under-
standable and accessible policy.
Second, information about the policies and information about COI within the policies
might be incomplete. We experienced several difficulties in locating COI policies from web-
sites and in obtaining a complete and clear picture of the actual information required to be
disclosed, the process of reviewing and the management of COI for the entire guideline devel-
opment process. Some organisations published their COI policies as a complete self-contained
document on their website, whereas others included information on identification and man-
agement of COI in their guideline methodology document. In some instances information was
interspersed among diverse parts of the guideline methodological document, the disclosure of
interest form and other supporting policies. Given the unstructured nature of the documents
retrieved we checked as far as possible for presence of information about COI. We also
encountered problems in the interpretation and coding of the information (e.g., on what
should be disclosed) given that there is not an agreed taxonomy of terms relating to COI.
Third, we restricted our study to organisations that produce guidelines on a wide range of
health topics and we excluded some professional organisations, which may limit the generaliz-
ability of our results. However, we would argue that our inclusion criteria would bias the sam-
ple towards organisations with greater resources for guideline development and therefore, if
anything, our results would underestimate the extent of the problem of inadequate COI man-
agement. However our study has the strength of including 29 organisations from 19 different
countries and one intergovernmental organisation in the sample and a content analysis of doc-
uments in four different languages. In terms of countries and languages represented, this may
be a more representative sample of guideline development organisations than those obtained
in other studies of COI in guidelines.
Conclusions
The finding that some organisations despite the recommendations and standards issued
respectively in 2009 [13], 2011 [14] and 2012 [15] still do not have COI policies publicly avail-
able is concerning. Also troubling was the failure of many policies to clearly report on critical
steps of obtaining, managing and communicating disclosure of relationships of interest. These
problems in addition to the existing variation among policies may increase the scope for
inconsistency in addressing COI issues; furthermore, unclear and incomplete COI policies
may confuse readers, erode public confidence, and decrease trust in guidelines and the organi-
sations that produce them. Thus, it is in the interest of guideline users and developers to
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promote strong adherence to the standards available on COI in conjunction with better scien-
tific journal policies so that every guideline is completed by a harmonized, complete, under-
standable, and accessible COI policy.
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